Acebron

Quick links to important sections

Acebron

Method of action: Anticoagulant

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acebron

Here is a quick overview of the medicine Acebron:

Property Description
Active Ingredient Acebrophylline
Form Oral Capsule or Tablet (often Sustained Release)
Pharmacological Class Airway Relaxant (Bronchodilator) & Mucus Thinner (Mucolytic)
General Purpose To improve airflow and clear secretions in the lungs
Origin Synthetic (Man-made)

What Type of Medicine is Acebron?

Acebron is a product containing the active ingredient Acebrophylline, a synthetic compound recognized for its beneficial effects on the respiratory system. It falls into the pharmacological category of Airway Relaxants (bronchodilators) and Mucus Thinners (mucolytics), a dual-action approach recognized for its role in respiratory support. This distinction is clinically recognized for providing a comprehensive approach to breathing difficulties, addressing both the narrowing of air passages and mucus buildup.

Acebron is commonly available as an oral capsule or tablet (often in a sustained-release form), and it is typically classified as a Prescription Drug (Rx). The active ingredient, Acebrophylline, is widely used across the world, reflecting its role in managing conditions that involve both airway constriction and excessive mucus.


What is the General Purpose of Acebron?

The primary purpose of Acebron is to help maintain open airways and facilitate the clearance of secretions, offering relief from feelings of chest congestion. The medicine achieves this by simultaneously addressing two factors: it relaxes the muscles that surround the breathing tubes and acts to make the thick, sticky mucus less dense and easier to cough up.

This combined action helps improve the overall flow of air both into and out of the lungs. For people experiencing breathing problems due to congestion, this dual benefit provides support for smoother, easier breathing by addressing airway irritation and blockages.

What side effects are possible with Acebron?

Possible Side Effects and Safety Information

The safety profile of Acebron, which contains Acebrophylline, is characterized by adverse reactions grouped according to the official System-Organ-Classes (SOCs) found in regulatory documentation. The most frequently observed effects relate to the Gastrointestinal System and Nervous System.


Adverse Reaction Classification

System-Organ-Class Common/Expected Reactions
Gastrointestinal Disorders Nausea, vomiting, stomach discomfort, epigastric pain, and diarrhoea.
Nervous System Disorders Headache, dizziness, insomnia (sleeplessness), and restlessness.

Serious Adverse Reactions and Risk

The most serious events documented in regulatory sources are associated with excessively high levels of the active ingredient in the bloodstream. These concentration-dependent risks include Serious Ventricular Arrhythmias and Convulsive Seizures (generalized tonic-clonic type). Additionally, there are documented reports of rare but significant reactions, such as Hypersensitivity Reactions and Serious Cutaneous Adverse Reactions (e.g., Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis), which necessitate immediate discontinuation of treatment if signs appear.


Population-Specific Safety Constraints

Official labels define specific safety constraints for vulnerable populations. The medicine is generally not recommended during breast-feeding and requires caution during pregnancy. Furthermore, older adults and individuals with severe hepatic (liver) or renal (kidney) alteration require particular caution, with severe impairment being listed as a contraindication due to the risk of slowed drug clearance leading to elevated blood concentrations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Acebron (Acebrophylline), a xanthine derivative, documents specific systemic manifestations of overdose. Initial signs frequently affect the gastrointestinal system, including severe and continued vomiting and nausea. Central Nervous System (CNS) effects may also appear, such as tremors, restlessness, and headache. Cardiovascular disturbances, specifically rapid or irregular heartbeats, are documented clinical signs.

Overdose is classified by regulators as a condition that can result in life-threatening outcomes. This includes the risk of seizures, which are explicitly documented in regulatory materials as potentially resulting in death or permanent brain damage. Due to these severe risks, individuals must seek emergency medical attention immediately if overdose is suspected. Government guidance mandates calling the Poison Help line for necessary instruction.

Management is limited to symptomatic and supportive treatment, as no specific antidote is known for this class of drug. Treatment involves intensive supportive care and frequent blood testing to monitor concentration. An increased risk of toxicity is noted in specific populations, including the elderly and patients with hepatic cirrhosis.

Therapeutic Uses of Acebron

What Acebron Treats: Main Uses and Benefits

Acebron is commonly used across conditions presenting with acute episodes and is relevant in clinical settings that involve acute or unstable symptom patterns, such as COPD, asthma, and chronic bronchitis. The medication is intended to assist in the management of symptoms associated with chronic lung diseases. It helps address symptom clusters that may become intense or disruptive, such as wheezing, shortness of breath, chest tightness, and issues with thick mucus clearance.

The medication is commonly used during phases when symptoms become more noticeable, applied in scenarios where additional management of discomfort is required. The main therapeutic aim is to support symptomatic relief that helps patients cope more steadily with difficult episodes.


The main therapeutic aim is to support symptomatic relief that helps patients cope more steadily with difficult episodes.


Quick Fact: Relief for Airway Discomfort

Acebron contributes to improved day-to-day comfort by assisting with functional stability when symptoms interfere with routine activities.

Regulatory References

  1. Theophylline: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Acebron?

The official eligibility for Acebron (Acebrophylline) is determined by regulatory authorities based on specific contraindications, pre-existing health conditions, and patient life stage.


Absolute Contraindications (Must Not Use)

Use of Acebron is strictly forbidden for individuals with a known hypersensitivity to Acebrophylline or related compounds, such as xanthine derivatives (like theophylline) or Ambroxol. It is also contraindicated in patients with a recent history of Acute Myocardial Infarction (heart attack), severe uncontrolled cardiac arrhythmias, and those experiencing hypotensive conditions (low blood pressure).

Additionally, the medicine is contraindicated for patients diagnosed with severe hepatic or severe renal alteration (severe liver or kidney disease), and for women who are breast-feeding.


Conditional Use and Restrictions

Certain populations require caution and close monitoring as defined in official labeling:

  • Organ Function: Patients with non-severe hepatic or renal impairment.
  • Comorbidities: Individuals with peptic ulcers, hyperthyroidism, congestive heart failure, or a history of seizure disorders.
  • Age and Life Stage: Older adults require caution due to increased risk of side effects. Use in younger children requires medical supervision. In pregnancy, use is avoided in the first months and strictly limited thereafter.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acebron (Acebrophylline) interactions are primarily governed by its metabolic breakdown into Theophylline, a substance whose clearance can be significantly modified by other medications. This section outlines officially documented interaction patterns based on regulatory prescribing information.


Documented Exposure-Modifying Interactions

Co-administration with certain medicinal products can alter the plasma concentration of Acebron's active metabolite, which may necessitate monitoring.

Interaction Effect Examples of Interacting Medicinal Products
Increase Levels / Reduce Clearance Cimetidine, Ciprofloxacin, Erythromycin, Allopurinol, Verapamil, Oral Contraceptives
Decrease Levels / Increase Clearance Carbamazepine, Barbiturates (e.g., Phenytoin)

Pharmacodynamic and Additive Effects

Regulatory documents highlight combinations where effects may overlap or be amplified:

  • Other Xanthine Derivatives: Co-use with other xanthine preparations is generally advised against due to the heightened risk of adverse effects from elevated levels.
  • Diuretics and Corticosteroids: Concomitant use with drugs like Furosemide or corticosteroids requires caution as it may worsen low blood potassium levels (hypokalemia).

Lifestyle and Population Considerations

  • Alcohol and Caffeine: Consumption of alcohol and high amounts of caffeine should be limited or avoided as they may increase the risk of side effects.
  • Smoking: Tobacco smoking is officially noted to reduce the plasma half-life of Theophylline, potentially affecting Acebron's clearance.
  • Organ Impairment: Caution is required in the elderly and those with hepatic or renal impairment, as reduced drug clearance can lead to higher serum levels and increased risk of accumulation.

Mechanism of Action

Acebron exerts its pharmacodynamic activity through two primary mechanistic domains.

Enzyme-Mediated Signaling Modulation

Acebron functions primarily as an inhibitor of the enzyme phosphodiesterase (PDE). This interaction modifies early molecular steps within the cell by preventing the hydrolysis of cyclic AMP (cAMP). The resulting increase in intracellular cAMP levels leads to the activation of protein kinase A (PKA), causing the relaxation of bronchial smooth muscle.

Mediator and Secretion Regulation

The drug modulates key signaling pathways by influencing inflammatory cells and mediators. This action involves the inhibition of inflammatory cell activation and the modulation of inflammatory mediator release, such as cytokines. Additionally, Acebron affects systems within the airways by stimulating the production of pulmonary surfactant. This initiates signaling sequences that influence mucosal transport and modify the rheological properties of bronchial secretions.

Dosage and Administration Information

How to Use Acebron

The administration of Acebron is established to ensure appropriate delivery and absorption. The medication is an Oral Route therapy, available as capsules, tablets (including sustained-release forms), or as a syrup.

Instruction Detail
Route of administration Exclusively Oral Route.
Dosing schedule The standard adult regimen is typically 100 mg twice daily (BID) or 200 mg once daily (QD) for sustained-release (SR) products.
Timing in relation to meals Must be taken with or immediately after food/meals to align with instructions regarding gastrointestinal tolerance.
Preparation requirements Oral liquids must be accurately measured. Solid dosage forms require no preparation.
Age-group administration rules Dose adjustment is specified for older adults and for patients with hepatic or renal impairment. Specific, lower dosing regimens are also detailed for various pediatric age groups.
Missed-dose rules If a dose is missed, the general protocol is to take it as soon as remembered; however, if the next dose is nearly due, the missed dose should be skipped entirely to avoid taking a double dose.
Special procedural conditions Tablets and capsules, particularly SR forms, must be swallowed whole and must not be crushed or chewed as this compromises the drug’s controlled-release mechanism.

The medication is prescribed for use over time, supporting both short-term management of acute respiratory symptoms and as part of a longer-term maintenance plan for chronic conditions.


Connection to the overall use protocol

The administration protocol involves consistent daily oral intake, with the specific instruction to coordinate dosing with meals to mitigate common digestive issues. This structured approach requires procedural compliance, including the critical restriction on altering the tablet or capsule structure to preserve the drug's designed release rate. The regimen is further tailored by specific dose adjustments for populations like older adults and individuals with hepatic or renal impairment, aligning the use protocol with standard prescribing parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acebron (Acebrophylline)

The available research for Acebron (Acebrophylline) consists mainly of clinical trials and comparative studies that examine its evaluation alongside other established respiratory medications. The research describes patterns observed in how patients reported their experience and how physiological outcomes related to breathing capacity were measured during the study periods. The evidence contributes to the body of research concerning short-term changes, and research highlights areas where long-term or broader data are still emerging.


Evidence for use in Chronic Obstructive Pulmonary Disease (COPD)

Research has primarily examined Acebron as an add-on treatment for adults diagnosed with moderate to severe COPD, conditions characterized by functional limitations and periods of heightened symptoms. Researchers explored outcomes related to physical discomfort by monitoring changes in Pulmonary Function Tests (PFTs), such as the Forced Expiratory Volume in 1 second (FEV1). These findings describe group patterns observed in the studies related to breathing function and patient comfort.

However, the certainty remains low regarding the role of this medicine in major COPD treatment strategies. While research monitored changes measured during the study period, the drug is not a preferred agent in major international clinical guidelines (e.g., GOLD). This position is often related to the fact that the available evidence is limited by the modest sample sizes used in most comparative trials and the focus is often on short-term markers.


Evidence for use in Bronchial Asthma

Research evaluating Acebron in Bronchial Asthma is primarily derived from short-term comparative Randomized Controlled Trials (RCTs). Studies monitored changes in PFTs and outcomes reflecting daily functioning or activity level using established asthma control scores. Findings describe patterns observed in the studies regarding how symptoms evolved in the observed populations.

Despite these findings, comparative evidence is lacking when Acebron is positioned against alternative therapies that are preferred in major guidelines. The current research provides limited data regarding long-term asthma control.


Research on Long-Term Use and Durability

The evidence base is largely relevant in trials assessing short-term or episodic symptom patterns, with follow-up durations commonly limited to 3 to 6 months. As a result, long-term effects are not yet fully established. There is limited information for long-term outcomes such as whether the initial changes in lung function persist over several years, or whether the medicine was studied using the frequency of serious exacerbations or hospitalizations as a long-term outcome measure.


Understanding the Research Landscape and Gaps

Overall, the evidence quality varies across studies, with sample sizes being modest in many of the key comparative trials. Specifically, certainty remains low regarding its role as a first-line or primary maintenance therapy in the context of major global treatment guidelines. More extensive research is ongoing and still needed to contribute more data on the use of Acebron in diverse patient populations.

Key Studies & References

  1. A comparative study of efficacy and safety of montelukast versus acebrophylline as add-on therapy to inhaled corticosteroids in bronchial asthma - National Journal of Physiology, Pharmacy and Pharmacology
  2. Comparative Study On Safety And Efficacy Of Theophylline Vs Acebrophylline In The Treatment Of COPD. - African Journal of Biomedical Research
  3. Chronic Use of Theophylline and Mortality in Chronic Obstructive Pulmonary Disease: A Meta-analysis | Archivos de Bronconeumología

Frequently Asked Questions (FAQ)

Common questions about Acebron (FAQ)


Q: How long does it typically take to feel the effects of Acebron?

Studies and official information indicate that the time to reach peak concentrations or the start of noticeable effects can range from one day up to about one week. This timeframe varies based on the formulation used and the specific respiratory condition being managed. The precise experience of effect onset is individual and is often discussed within the context of the specific respiratory condition being managed.


Q: Does Acebron have a withdrawal effect when stopping it?

Official regulatory warnings advise against the abrupt discontinuation of Acebron therapy. Stopping the medicine suddenly may lead to a return of the original respiratory symptoms or other discontinuation effects, such as a headache or feelings of restlessness. Discontinuation of the medication is a matter of professional medical management.


Q: Does Acebron affect my ability to drive or operate machinery?

While the official product information does not generally state that the medication impairs the ability to drive, official documentation advises that caution is appropriate due to the possibility of dizziness, a noted side effect. Activities requiring full mental alertness are generally managed with caution until the drug's personal effect is understood.


Q: Is Acebron addictive or habit-forming?

According to the official drug profiles and regulatory information, Acebron is not classified as an addictive substance. There are no reported tendencies for the medication to be habit-forming.


Q: Is Acebron considered a high-risk drug?

Acebron is a prescription drug that contains an active ingredient from the xanthine derivatives class. The profile lists serious risks such as Serious Ventricular Arrhythmias and Convulsive Seizures associated with excessively high blood levels of the active ingredient. The safety profile is often described in regulatory sources in relation to other compounds within this class.


Q: Why do doctors choose Acebron over other options for [condition]?

The main rationale cited for using Acebron is its unique dual mechanism of action, as described in regulatory documents. The drug acts simultaneously as both an airway relaxant (a bronchodilator) and a mucus thinner (a mucolytic). This combined function is what distinguishes it from single-action respiratory medications.


Q: Is Acebron the same as [common similar drug name]?

Acebron is the brand name for the single active ingredient, Acebrophylline. This ingredient is described as a compound that combines a bronchodilator component and a mucus-regulating component in one substance. This composition makes it distinct from products that contain only one of these therapeutic components.


Q: How long can a person safely stay on Acebron treatment?

Official prescribing information notes that Acebron is approved for both short-term management of acute symptoms and as part of a longer-term maintenance plan. The actual duration of treatment is not a fixed period. The necessity for continued use is assessed as part of the established medical management plan.


Q: Is it true that Acebron is used for more than just [main use]?

Yes, the medication is officially indicated for more than one specific respiratory problem. Regulatory documents list its use in managing chronic obstructive pulmonary disease (COPD) and bronchial asthma, as well as chronic bronchitis. Its general purpose is to improve airflow and facilitate the clearance of secretions for various related respiratory conditions.


Q: Are there any restrictions on working or physical activity while taking Acebron?

There are no general restrictions on working or physical activity noted in the official prescribing information. However, patients should be mindful that dizziness is a documented side effect. A cautious approach is generally taken when performing activities that require balance or full mental alertness until the drug's personal effect is understood.


Q: Where can I find the official regulatory document (like FDA label or SmPC) for Acebron?

Official regulatory information about Acebron is maintained by national drug authorities worldwide. These documents include the Summary of Product Characteristics (SmPC) from agencies like the EMA or MHRA, and the official drug labels or DailyMed entries published by the FDA.


Q: Why do some people need a higher dose of Acebron than others?

Regulatory guidance specifies that dose adjustments may be needed for certain patient populations, which accounts for the variation in prescribed doses. This includes older adults and patients who have known alterations in their hepatic (liver) or renal (kidney) function. This tailoring helps to maintain the appropriate drug concentration in the body.

How should Acebron be stored and disposed of?

How to Store and Dispose of Acebron (Acebrophylline)

The storage and disposal of Acebron must strictly follow the conditions specified in the official regulatory labeling to ensure the medicine's stability and efficacy.


Storage Requirements

Acebron must be stored at a temperature below 25 C (77 F) in a dry place. It is essential to keep the container tightly closed to protect the contents from moisture and degradation. The medicine must not be frozen.

Child Safety and Disposal

Regulatory requirements mandate that Acebron, like all medicines, must be kept out of the sight and reach of children.

When disposing of unused or expired product, it must not be flushed down the toilet or poured into a drain. Disposal must be performed according to local regulations for unused medicine to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acebron found in:

A-Z Index: